Phase-appropriate Analytical Methodology

News
Article
Pharmaceutical TechnologyPharmaceutical Technology Quality and Regulatory Sourcebook March 2023
Volume 2023 eBook
Issue 2
Pages: 4-6

A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.

Murrstock - Stock.adobe.com

Murrstock - Stock.adobe.com

Progressing a drug candidate from research to commercialization requires huge sums of money (approximately US$1.5 billion–$4.5 billion) (1) and is inherently high risk due to the high attrition rate. Only approximately
10% of total drug attrition is because of poor strategic planning or a lack of commercial needs (2). Highlighting solid strategy and funding alone is not enough to take a drug to market. Approximately 70–80% of clinical failures can be attributed to a lack of clinical efficacy or toxicity (3),
and the majority of drug failures occurring in pre-clinical and Phase I are due to pharmacokinetics or toxicity issues (4).

Read this article in Pharmaceutical Technology's March 2023 Quality and Regulatory Sourcebook eBook.

About the author

Paul Van Tilborg is director of analytical sciences at Ardena.

Article details

Pharmaceutical Technology
eBook: Quality and Regulatory Sourcebook
March 2023
Pages: 4-6

Citation

When referring to this article, please cite it as Van Tilborg, P. Phase-appropriate Analytical Methodology. Pharmaceutical Technology's Quality and Regulatory Sourcebook eBook (March 2023).

Recent Videos
Drug Digest: Strategic Partnerships
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.